GlassScriptPhysician profile
Morgan Hoffman
NPI 1467044669
$11,559.14
in general payments reported to CMS, 2019-2025
31 companies · $3,538 in 2025
The $3,538 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,215 · 2024: $4,807 · 2025: $3,538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,375.15 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,324.59 | 2023-2025 | |
| Amgen INC. | $1,123.82 | 2023-2025 | Evenity, Enbrel, Otezla |
| Ucb, INC. | $956.30 | 2023-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $909.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $893.77 | 2023-2025 | Benlysta |
| Janssen Biotech, INC. | $673.60 | 2023-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $573.03 | 2023-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $523.24 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $517.57 | 2023-2025 | Acthar |
| Genzyme Corporation | $322.06 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $259.87 | 2024-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $247.72 | 2023-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.36 | 2023-2025 | Ofev, Cyltezo |
| Scilex Pharmaceuticals INC. | $168.56 | 2024-2025 | |
| Csl Behring | $130.91 | 2024-2025 | Hizentra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Organon LLC | $80.70 | 2024-2025 | Hadlima, Nexplanon |
| Alexion Pharmaceuticals, INC. | $76.53 | 2024 | Strensiq |
| Kyowa Kirin, INC. | $72.77 | 2024 | Crysvita |
| Aurinia Pharma U.S., INC. | $51.66 | 2024 | Lupkynis |
| Sandoz INC. | $48.63 | 2023 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $47.53 | 2023-2024 | Cuvitru |
| Fresenius Kabi USA, LLC | $40.14 | 2023-2024 | Idacio |
| Lilly USA, LLC | $29.43 | 2025 | Zepbound, Taltz |
| Axsome Therapeutics, INC. | $25.96 | 2025 | Sunosi |
| Almatica Pharma LLC | $23.94 | 2024 | Teriparatide |
| Radius Health, INC. | $23.24 | 2023 | Tymlos |
| Ibsa Pharma INC. | $22.56 | 2024 | Tirosint, Licart |
| Genentech USA, INC. | $21.70 | 2024 | Actemra |
| Collegium Pharmaceutical, INC. | $19.73 | 2024 | Xtampza |
| Sobi, INC | $18.65 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.